Menlo Park's Auxogyn, Inc. Snags $34 Million for IVF Test That Can Tell if an Embryo is Viable

In vitro fertilization is a tough process. Even if a set of embryos are able to form, it’s a real crapshoot to see which – if any – will actually be viable. Bay Area biotech Auxogyn has developed a test to track whether an embryo is developing successfully – and has raised a healthy swath of cash to commercialize its fresh-on-the-market product, the Eeva Test.

The company recently pulled in $34 million, according to a new regulatory filing.

Help employers find you! Check out all the jobs and post your resume.

Back to news